Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Share-based Compensation: 2016-2025

Historic Share-based Compensation for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $3.2 million.

  • Akebia Therapeutics' Share-based Compensation rose 95.69% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 28.83%. This contributed to the annual value of $7.8 million for FY2024, which is 16.55% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Share-based Compensation is $3.2 million, which was up 20.37% from $2.7 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Share-based Compensation high stood at $6.9 million for Q2 2022, and its period low was $1.5 million during Q4 2023.
  • In the last 3 years, Akebia Therapeutics' Share-based Compensation had a median value of $2.2 million in 2025 and averaged $2.3 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Share-based Compensation crashed by 50.21% in 2023, and later soared by 95.69% in 2025.
  • Akebia Therapeutics' Share-based Compensation (Quarterly) stood at $4.6 million in 2021, then tumbled by 34.40% to $3.0 million in 2022, then crashed by 50.21% to $1.5 million in 2023, then climbed by 12.09% to $1.7 million in 2024, then surged by 95.69% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $2.7 million for Q2 2025, and $2.2 million during Q1 2025.